Imatinib mesylate: A designer drug.
Article
in English
| IMSEAR
| ID: sea-94040
ABSTRACT
Molecularly targeted therapy is a novel approach in cancer treatment. Imatinib, a specific tyrosine kinase inhibitor, since its inception in 1990s, has become the first-line drug in management of chronic myelogenous leukemia (CML) chronic phase. It has also shown promising results in treatment of gastro-intestinal stromal tumors, clonal eosinophilic disorders and Philadelphia chromosome positive acute lymphatic leukemia. The efficacy of imatinib has geared up further research into development of designer drugs with molecular targets. This review gives a comprehensive description of the development, biology, utility, dosing, and limitations of imatinib mesylate.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Piperazines
/
Pyrimidines
/
Philadelphia Chromosome
/
Humans
/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Gastrointestinal Stromal Tumors
/
Protein Kinase Inhibitors
/
Eosinophilia
/
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Language:
English
Year:
2006
Type:
Article
Similar
MEDLINE
...
LILACS
LIS